Clinical Trial Endpoint by Counting Hairs - Story of Clinical Trials in Androgenetic Alopecia (Hair Loss)

 

The clinical development landscape for androgenetic alopecia (AGA) has undergone a dramatic transformation, culminating in the recent announcement by Veradermics, Inc. regarding their pivotal Phase 2/3 study for VDPHL01. On April 27, 2026, the company reported that its extended-release oral minoxidil formulation achieved its primary endpoints in a study of 519 men with mild-to-moderate pattern hair loss, marking a potential shift in the first-line treatment of a condition that affects approximately 80 million individuals in the United States alone. While the therapeutic innovation lies in the proprietary gel matrix delivery system, the scientific validation of the drug’s efficacy rests upon a surprisingly literal metric: the counting of individual hairs within a fixed area of the scalp. This primary efficacy measure, known as the change from baseline in non-vellus Target Area Hair Count (TAHC) using digital image analysis at Month 6, represents the gold standard for objective evidence in hair restoration trials. 

Clinical Significance of the Veradermics Study '302'

The Veradermics Study '302' was a randomized, double-blind, placebo-controlled Phase 2/3 trial designed to evaluate the efficacy and safety of VDPHL01, an 8.5 mg oral tablet administered either once daily (QD) or twice daily (BID). The results demonstrated a robust increase in hair density that significantly surpassed both the placebo arm and historical benchmarks for topical treatments. Specifically, at Month 6, the mean non-vellus TAHC increased by 30.3 hairs/cm^2 in the QD arm and 33.0 hairs/cm^2 in the BID arm, compared to a nominal increase of 7.3 hairs/cm^2 in the placebo group.

This efficacy signal is particularly noteworthy given the mechanism of oral minoxidil. Traditionally, oral minoxidil has been restricted by cardiovascular risks, including tachycardia and fluid retention, caused by the rapid peak plasma concentrations of immediate-release formulations. The VDPHL01 formulation utilizes an extended-release technology that avoids these high peaks while maintaining drug levels above the minimum hair growth threshold for longer durations. This pharmacokinetic optimization appears to translate directly into the high hair counts recorded in the '302' trial.

Efficacy Data from Veradermics Study '302'

The following table summarizes the key hair count outcomes and patient-reported measures from the topline results, highlighting the statistical separation achieved by the extended-release formulation.

Endpoint (Month 6)	VDPHL01 8.5 mg QD (n=173)	VDPHL01 8.5 mg BID (n=173)	Placebo (n=173)	Statistical Significance (p-value)
Mean  Non-Vellus TAHC (hairs/cm^2)	+30.3	+33.0	+7.3	< 0.0001
Patients with 'Improved' or 'Much Improved' PRO (%)	48.4%	62.9%	13.4%	< 0.0001
Any Patient-Reported Improvement (%)	79.3%	86.0%	35.6%	< 0.0001
Investigator-Rated Improvement (IGA) (%)	72.0%	84.4%	35.6%	< 0.0001

The magnitude of these results exceeded the "market opportunity" bar set by analysts, which suggested that a gain of 15–20 hairs/cm^2 would be sufficient to establish a multi-billion dollar commercial presence. By doubling this threshold in the BID arm, Veradermics has underscored the utility of TAHC as a definitive measure of pharmacological power.

The Technical Mechanics of Target Area Hair Counting

The process of measuring TAHC is an intricate marriage of dermatology and computational image analysis, designed to eliminate the subjectivity inherent in visual "global photography". In contemporary clinical trials, the TAHC endpoint refers to the quantification of hair follicles within a precise 1 cm^2 region of the scalp, usually located at the vertex or the leading edge of thinning.

The Non-Vellus Distinction and Miniaturization

Central to the TAHC metric is the distinction between vellus and terminal (non-vellus) hairs. AGA is fundamentally a disease of follicular miniaturization, wherein terminal hairs—large, pigmented, and thick—are progressively replaced by vellus hairs—fine, short, and unpigmented. Terminal hairs typically have a shaft diameter greater than 30 um (or 40 um in some specific protocols), while vellus hairs fall below this threshold.

From a regulatory and clinical standpoint, only the increase in non-vellus hairs is considered a successful outcome, as vellus hairs do not contribute significantly to the visible coverage or aesthetic density of the scalp. In the Veradermics study, the non-vellus cutoff was specifically defined as hairs greater than 30 um in diameter. 

The Phototrichogram Procedure

The standard procedure for capturing TAHC data, often referred to as a phototrichogram or digital image analysis (DIA), involves several rigorous steps to ensure intra-subject consistency over time.

1.    Selection and Tattooing: The investigator identifies a target area of thinning. To ensure that exactly the same 1cm^2 of skin is evaluated at Baseline, Month 3, and Month 6, a small ink dot tattoo is applied to the center of the site. This tattoo serves as a permanent reference point for the camera system.

2.    Hair Clipping: Within a circular area around the tattoo, the hair is clipped to a uniform length of approximately 1 mm. This clipping is essential because it allows the digital sensor to view the hair shaft "end-on" or in a very short segment, facilitating precise diameter measurement at the skin's surface.

3.    Contrast Enhancement: In many trials, especially those involving patients with fair, blonde, or gray hair, a hair dye is applied to the clipped area to darken the hair shafts. This increases the contrast between the hair and the scalp skin, which is vital for the automated counting algorithms.

4.    Digital Image Capture: A specialized macrophotography system (e.g., FotoFinder, TrichoScan) captures images of the 1 cm^2 target area at magnifications ranging from 20 X to 72 X.

5.    Automated Processing: The software identifies every hair within the frame, calculates its diameter, and provides a total count of non-vellus hairs.

 

Parameter	Standard Technical Requirement	Rationale
Area	1 cm^2	Standardized unit for density calculation.
Reference	Ink dot tattoo	Ensures longitudinal accuracy.
Length	clipping	Facilitates automated diameter measurement.
Diameter		Definition of terminal (non-vellus) hair.
Dye	Optional/Contrast-dependent	Required for fair/gray hair detection.

 

Critical Evaluation: Drawbacks and Technical Challenges

While TAHC is hailed as an objective "gold standard," it is not without significant technical and practical drawbacks that can introduce variability and compromise trial integrity. 

Algorithmic and Software Errors

Automated digital image analysis systems, such as TrichoScan, are prone to specific detection errors. One significant issue is "fragmentation," where the software incorrectly breaks a single hair strand into two or more segments. This typically occurs at the exit point from the follicle, where varied pigmentation can trick the sensor into seeing a gap, leading to a false elevation of the total hair count.

Furthermore, "crossing" or overlapping hairs present a major hurdle for AI-driven counting. In areas of high density or within follicular units where multiple hairs emerge from a single pore, the software often fails to resolve individual shafts, leading to an underestimation of hair density by as much as 10% to 30%. Some studies have found that while automated counts correlate well with manual counts, the absolute values can differ by 10% due to these resolution limitations. 

Patient and Operational Barriers

The requirement for a scalp tattoo is a significant deterrent for many potential study participants. While the tattoo is small, it is permanent, and the prospect of a lifelong mark on the scalp—even if intended to measure regrowth—can be a psychological barrier. Additionally, the necessity of clipping a patch of hair to 1 mm is aesthetically unappealing, particularly for men who are already self-conscious about their thinning hair. This can lead to recruitment challenges or high dropout rates in longer trials.

The "gray hair" problem remains one of the most persistent technical failures in TAHC. White or gray hair lacks the melanin necessary for the digital sensor to distinguish it from the background of the scalp skin. While dyeing the hair is a solution, it adds complexity to the site-level procedures and can result in artifacts—such as dye spots on the skin—being misidentified as hair follicles by the software. 

Statistical and Procedural Inconsistency

There is a lack of standardization across different clinical trials regarding the diameter cutoff for terminal hair. Some trials use 30 um, while others use 40 um or even 60 um in the context of hirsutism studies. This lack of uniformity makes it difficult to compare the efficacy of different drugs (e.g., comparing Veradermics' oral minoxidil to Kintor’s pyrilutamide) directly through TAHC results.

Drawback Category	Specific Technical Issue	Resulting Error
Detection	Fragmentation of hair shafts	Falsely elevated hair counts.
Resolution	Overlapping hairs in follicular units	Underestimation of hair density.
Contrast	Fair/Gray hair invisibility	Missing data or artifact miscounts.
Participant	Requirement for permanent tattoo	Reduced patient enrollment/compliance.
Procedural	Patch clipping to 1 mm	Aesthetic distress for the patient.

 

Regulatory Alignment: The "Feel, Function, and Survival" Framework

The Food and Drug Administration (FDA) evaluates the clinical benefit of any therapeutic intervention through the lens of Clinical Outcome Assessments (COAs), which must demonstrate a positive effect on how an individual feels, functions, or survives. 

Survival and Physical Function

In the case of androgenetic alopecia, the categories of "survival" and "physical function" are generally inapplicable. AGA is a biologically benign condition; it does not shorten the lifespan, nor does it impair physical mobility or organ systems. Unlike alopecia areata, which may be associated with systemic immune disorders, AGA is a localized process of hormone-mediated follicular miniaturization. 

Psychosocial "Feeling" and Identity

Where AGA trials gain regulatory traction is in the "feels" pillar. Hair loss is deeply intertwined with self-image, confidence, and psychological health. Clinical data shows that patients with pattern hair loss frequently suffer from depression, low self-esteem, and social withdrawal.

The FDA increasingly prioritizes Patient-Reported Outcomes (PROs) alongside objective measures like TAHC. For a drug to be approved, the increase in hair count must correlate with a perceptible improvement in how the patient feels about their appearance. In the Veradermics trial, the co-primary endpoint was the Androgenetic Alopecia Impact Rating Scale (AAIRS), a PRO that confirmed that the robust hair count gains (30-33 hairs/cm^2) were indeed meaningful to the patients. 

TAHC as an Objective Biomarker

Technically, TAHC is classified more as an objective biomarker of biological activity rather than a direct measure of how a patient feels or functions. While a patient does not "feel" an individual hair growing, they feel the aggregate effect of thousands of such hairs. Thus, TAHC provides the "what" (the biological regrowth), while the PRO provides the "so what" (the clinical benefit).

FDA Pillar	Relevance to AGA	Measurement Tool
Survives	Not Relevant	N/A
Functions	Psychosocial Functioning	PRO Scales (e.g., AAIRS, MHGQ)
Feels	Emotional Well-being	PRO Scales and Global Assessments
Objective Evidence	Biological Regrowth	Target Area Hair Count (TAHC)

The Disease vs. Lifestyle Debate in Androgenetic Alopecia

The medicalization of hair loss is a central theme in dermatological policy. Whether AGA is viewed as a "disease" or a "lifestyle concern" dictates the level of regulatory scrutiny and the likelihood of insurance reimbursement.

The Argument for "Lifestyle"

Critics of the pharmaceutical industry often characterize the treatment of baldness as "lifestyle" medicine, akin to treating wrinkles or minor skin imperfections. This perspective stems from the fact that hair loss is a near-universal feature of aging in men, affecting 50% by age 50 and 80% by age 70. From this viewpoint, TAHC is merely a cosmetic tally of aesthetic units rather than a clinical resolution of a pathological state. 

The Argument for "Disease"

Modern dermatology, however, highlights the pathological mechanisms of AGA—specifically the over-expression of 5-alpha reductase and the resultant high levels of dihydrotestosterone (DHT) that cause follicular atrophy. Furthermore, the psychological morbidity associated with AGA is comparable to that of more "traditional" skin diseases like psoriasis or atopic dermatitis. Younger patients, in particular, show significantly reduced health-related quality of life (HRQoL), with symptoms of distress that impact their social and professional trajectories.

The Veradermics pivotal win is seen by many experts as a validation of the "disease" model, as the FDA’s acceptance of a Phase 3 program for an oral drug implies that the condition is significant enough to warrant a systemic intervention with a carefully evaluated safety-to-efficacy ratio. 

Competitive Analysis and Benchmarking of TAHC Results

To understand the magnitude of the Veradermics results, one must compare the TAHC gains of VDPHL01 against other historical and emerging treatments in the AGA space. 

Comparative Hair Count Performance

The efficacy of various treatments is often compared through the "mean change from baseline" in non-vellus hairs over a 12 to 48-week period.

Compound	Formulation	TAHC Increase (hairs/cm2)	Study Duration
VDPHL01 (Veradermics)	Oral Extended-Release Minoxidil	+33.0 (BID)	24 Weeks
Propecia (Finasteride)	Oral 1 mg Tablet	+7 to +18 (varies)	48 Weeks
GT20029 (Kintor)	Topical PROTAC	+10 to +15 (est.)	12 Weeks
Clascoterone (Cosmo)	Topical 5% Solution	5.39x relative vs. placebo	24 Weeks
Topical Dutasteride	0.05% Solution	Significant vs. Finasteride	24 Weeks
Minoxidil (Topical)	5% Foam/Solution	+12 to +18	48 Weeks

Insights from the Comparison

The Veradermics BID result of 33.0  hairs/cm^2 at Month 6 is nearly double the typical performance of topical minoxidil or oral finasteride reported in historical FDA labels. This discrepancy suggests that the extended-release oral route provides a more consistent follicular stimulation than either topical application (which is limited by absorption and sulfotransferase activity) or traditional 5-alpha reductase inhibitors (which only target one pathway of miniaturization).

Topical clascoterone and pyrilutamide are also generating significant TAHC data, with clascoterone showing up to a 539% relative improvement over vehicle in specific trials. These large percentage increases can sometimes be misleading, however, as they depend heavily on the baseline hair count of the patient population. The absolute count (the hairs/cm^2 metric) remains the most transparent way to bench-press different treatments.

Future Directions in Hair Loss Quantification

As the industry moves beyond traditional small molecules toward regenerative medicine and cell-based therapies, the ways we measure hair growth are likely to evolve. 

Beyond the Binary Count

Researchers are increasingly looking at metrics that go beyond the simple presence or absence of a hair shaft. These include:

●     Cumulative Hair Width (CHW): A measure that combines the number of hairs with their individual diameters to provide an "area of coverage" metric.

●     Terminal-to-Vellus (T/V) Ratio: An indicator of the health of the follicular population, measuring the success of miniaturization reversal.

●     Anagen-to-Telogen Ratio: Measured via phototrichogram, this indicates the percentage of hairs in the active growth phase versus the resting phase. 

The Role of Regenerative Medicine

Emerging therapies like Pelage’s PP405 or Xtressé’s Xvie injectable focus on reactivating dormant stem cells within the follicle. In these cases, TAHC may be used to measure the "induction" of new terminal hairs from follicles that were previously invisible or clinically dead. This shift from "growth phase support" to "follicular regeneration" will require even more sensitive digital image analysis tools that can detect early-stage hair shaft formation. 

Conclusion: The Resilient Utility of Hair Counting

The Veradermics pivotal win has reaffirmed that, despite its perceived simplicity, the counting of hairs remains the most definitive instrument in the dermatological arsenal. The TAHC metric provides the objective, verifiable, and quantitative evidence required by regulatory bodies to distinguish a therapeutic breakthrough from a cosmetic claim. While the digital analysis methods are subject to technical limitations like fragmentation and contrast issues, their ability to document a 33.0 hairs/cm^2 increase offers a clear and measurable signal of pharmacological success.

Ultimately, the medicalization of androgenetic alopecia is justified not just by the biology of DHT and the 5-alpha reductase pathway, but by the measurable impact of regrowth on a patient’s identity and psychosocial functioning. As we look toward a future of oral non-hormonal therapies and regenerative injectables, the humble hair count will continue to serve as the primary arbiter of what constitutes a "clinically meaningful" result in the fight against pattern hair loss.